肺段切除与肺叶切除治疗隐匿性N1非小细胞肺癌:少即是多?
本研究基于前瞻性机构数据库2006年1月至2023年1月数据,纳入185例术中由cN0上调为pN1的非小细胞肺癌患者,其中30例(16.2%)行肺段切除、155例(83.8%)行肺叶切除。经倾向评分加权后,肺段切除与肺叶切除的5年总生存和无局部区域复发生存均无差异,术式不是结局预测因素。
要点
- 隐匿性N1患者中肺段切除与肺叶切除的5年总生存和无局部区域复发生存相似。
- 肺叶切除组病理肿瘤尺寸大于肺段切除组,但两组辅助治疗率无差异。
- 多变量分析中术式不是生存或复发的预测因素。
核心结论
- 对于隐匿性N1非小细胞肺癌患者,肺段切除与肺叶切除的总生存和无局部区域复发生存相似。
研究设计与样本
- 回顾性队列研究,基于前瞻性机构数据库2006年1月至2023年1月,纳入185例cN0上调为pN1的非小细胞肺癌患者。
- 排除接受新辅助治疗或超出目标肺段/肺叶的肺实质切除者,采用倾向评分加权控制混杂因素。
主要发现
- 185例隐匿性N1患者中,30例(16.2%)行肺段切除,155例(83.8%)行肺叶切除。
- 肺叶切除组病理肿瘤尺寸大于肺段切除组:3.4 cm(四分位距2.30-4.45 cm)vs 1.95 cm(四分位距1.43-2.83 cm),P < .005。
- 肺段切除与肺叶切除的辅助治疗率无差异(67% vs 70%,P = .7)。
- 中位随访60个月,倾向加权前后5年生存和无局部区域复发生存均无差异(加权总生存:79.69% vs 66.22%,log-rank P = .401)。
- 多变量分析中,术式不是生存和复发的预测因素。
临床怎么用
- 对于术中证实为隐匿性N1的非小细胞肺癌,肺段切除可作为肺叶切除的替代选择,无需常规转为肺叶切除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With widespread adoption of segmentectomy for early-stage non-small cell lung cancer (NSCLC), the need to convert segmentectomy to lobectomy for nodal disease comes into question. We aimed to determine whether extent of resection impacts overall survival or locoregional recurrence-free survival (LRFS) in patients with occult N1 NSCLC. METHODS: We identified patients who underwent segmentectomy or lobectomy for NSCLC and were upstaged from cN0 to pN1 in our prospective institutional database from January 2006 to January 2023. Patients receiving neoadjuvant treatment or parenchymal resection beyond the segment(s) or lobe of interest were excluded. Propensity score weighting was used to control for potential confounders. Overall survival and LRFS were evaluated using Kaplan-Meier curves and compared with log-rank tests. Cox proportional hazards regression was used to calculate hazard ratios. RESULTS: Of 185 patients with occult N1 disease, 30 (16.2%) underwent segmentectomy and 155 (83.8%) lobectomy. Patients undergoing lobectomy had larger pathologic tumor sizes than those undergoing segmentectomy (3.4 cm [interquartile range, 2.30-4.45 cm] vs 1.95 cm [interquartile range, 1.43-2.83 cm], P < .005). There was no difference in rates of adjuvant therapy between segmentectomy and lobectomy (67% vs 70%, P = .7). Median follow-up was 60 months. There were no differences in 5-year survival or LRFS between segmentectomy and lobectomy before or after propensity weighting (weighted overall survival: 79.69% vs 66.22%, log-rank P = .401). In multivariable analysis of survival and recurrence, procedure type was not a predictor of outcome. CONCLUSIONS: Segmentectomy is associated with similar overall survival and LRFS to lobectomy for patients with occult N1 NSCLC.
引用
- Abdallat M, Leo RT, Sugarbaker EA, et al. Segmentectomy vs Lobectomy for Occult N1 in Non-Small Cell Lung Cancer: Is Less More? Ann Thorac Surg. 2025. PMID: 40784649. doi:10.1016/j.athoracsur.2025.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。